Symptom scores in benign prostatic hyperplasia

Urology

Volumn 49, Issue 1, 1997, Pages 10-18

  Riehmann, Morten ^a   Hansen, Bo Jesper ^b   Polishuk, Paul V ^b   Nordling, Jørgen ^b   Hald, Tage ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE SEVERITY; HEALTH CARE COST; HUMAN; MORTALITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SURGICAL TECHNIQUE; SYMPTOMATOLOGY; WELLBEING;

EID: 0031027086     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00432-3     Document Type: Review

References (91)

1. Robson MC: The incidence of benign prostatic hyperplasia and prostatic carcinoma in cirrhosis of the liver. J Urol 92: 307-310, 1964.
2. Lytton B, Emery JM, and Harvard BM: The incidence of benign prostatic obstruction. J Urol 99: 639-645, 1968.
3. Glynn RJ, Campion EW, Bouchard GR, and Silbert JE: The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 121: 78-90, 1985.
4. Ekman P: BPH epidemiology and risk factors. Prostate 2(suppl): 23-31, 1989.
5. Boyle P, McGinn R, Maisonneuve P, and La Vecchia C: Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed. Eur Urol 20(suppl 1): 3-10, 1991.
6. Garraway WM, Collins GN, and Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 338: 469-471, 1991.
7. Holtgrewe HL: American Urological Association survey of transurethral prostatectomy and the impact of changing Medicare reimbursement. Urol Clin North Am 17: 587-593, 1990.
8. Holtgrewe HL, Mebust WK, Dowd JB, Cockett ATK, Peters PC, and Proctor C: Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol 141: 248-253, 1989.
9. Barry MJ, Cockett ATK, Holtgrewe HL, McConnell JD, Sihelnik SA, and Winfield HN: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 150: 351-358, 1993.
10. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia: the Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia. J Urol 150: 1696-1700, 1993.
11. Tsang KK, and Garraway WM: Impact of benign prostatic hyperplasia on general well-being of men. Prostate 23: 1-7, 1993.
12. World Health Organization: Basic Documents (39th ed). Geneva, Switzerland, 1992.
13. Ware JE Jr: Standards for validating health measures: definition and content. J Chronic Dis 40: 473-480, 1987.
14. Sutcliffe J, and Holmes S: Quality of life: verification and use of a self-assessment scale in two patient populations. J Adv Nurs 16: 490-498, 1991.
15. Slevin ML, Plant H, Lynch D, Drinkwater J, and Gregory WM: Who should measure quality of life, the doctor or the patient? Br J Cancer 57: 109-112, 1988.
16. Spector WD, Katz S, Murphy JB, and Fulton JP: The hierarchical relationship between activities of daily living and instrumental activities of daily living. J Chronic Dis 40: 481-489, 1987.
17. Katz S: The science of quality of life. J Chronic Dis 40: 459-463, 1987.
18. Levine S, and Croog SH: Quality of life and the patient's response to treatment. J Cardiovasc Pharmacol 7(suppl 1): S132-S136, 1985.
19. Troidl H, Kusche J, Vestweber KH, Eypasch E, Koeppen L, and Bouillon B: Quality of life: an important endpoint both in surgical practice and research. J Chronic Dis 40: 523-528, 1987.
20. Fayers PM, and Jones DR: Measuring and analyzing quality of life in cancer clinical trials: a review. Stat Med 2: 429-446, 1983.
21. Barry MJ, and O'Leary MP: Advances in benign prostatic hyperplasia: the developmental and clinical utility of symptom scores. Urol Clin North Am 22: 299-307, 1995.
22. Guyatt G, Walter S, and Norman G: Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 40: 171-178, 1987.
23. Kirshner B, and Guyatt G: A methodological framework for assessing health indices. J Chronic Dis 38: 27-36, 1985.
24. Bulpitt CJ, and Fletcher AE: Measurement of the quality of life in angina. J Hypertens Suppl 5: S41-S45, 1987.
25. Deyo RA, Diehr P, and Patrick DL: Reproducibility and responsiveness of health status measures. Controll Clin Trials 12: 1425-1585, 1991.
26. Christensen AH, Gjørup T, Hilden J, Fenger C, Henriksen B, Vyberg M, Østergaard, and Hansen BF: Observer homogeneity in the histological diagnosis of Helicobacter pylori: latent class analysis, kappa coefficient, and repeat frequency. Scand J Gastroenterol 27: 933-939, 1992.
27. Brasso K, Stigsby B, Pilsgard B, and Nordling J: Precision of a patient-weighted symptom score in prostatism: the DAN-PSS-1 questionnaire. Scand J Urol Nephrol 28: 71-75, 1994.
28. Bowker AH: A test for symmetry in contingency tables. J Am Stat Assoc 43: 572-574, 1948.
29. Kramer MS, and Feinstein AR: Clinical biostatistics: LIV. The biostatistics of concordance. Clin Pharmacol Ther 29: 111-123, 1981.
30. Guyatt GH, Bombardier C, and Tugwell PX: Measuring disease-specific quality of life in clinical trials. Can Med Assoc J 134: 889-895, 1986.
31. Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 16: 297-334, 1951.
32. Morrow GR: Clinical trials in psychosocial medicine: methodologic and statistical considerations. Part III. Assessing measurement techniques in psychosocial oncology. Cancer Treat Rep 64: 451-456, 1980.
33. Bolognese JA, Kozloff RC, Kunitz SC, Grino PB, Patrick DL, and Stoner E: Validation of a symptoms questionnaire for benign prostatic hyperplasia. Prostate 21: 247-254, 1992.
34. Guyatt GH, Feeny DH, and Patrick DL: Measuring health-related quality of life. Ann Intern Med 118: 622-629, 1993.
35. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT, and the Measurement Committee of the American Urological Association: The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148: 1549-1557, 1564, 1992.
36. Hanley JA: The robustness of the "binormal" assumptions used in fitting ROC curves. Med Decis Making 8: 197-203, 1988.
37. Hanley JA, and McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36, 1982.
38. Hald T, Nordling J, Andersen JT, Bilde T, Meyhoff HH, and Walter S: A patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 138: 59-62, 1991.
39. Hansen BJ, Flyger H, Brasso K, Schou J, Nordling J, Thorup Andersen J, Mortensen S, Meyhoff HH, Walter S, and Hald T: Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol 76: 451-458, 1995.
40. Fletcher AE, and Bulpitt CJ: Measurement of quality of life in clinical trials of therapy. Cardiology 75(suppl 1): 41-52, 1988.
41. Bulpitt CJ, and Fletcher AE: Drug treatment and quality of life in the elderly. Clin Geriatr Med 6: 309-317, 1990.
42. Barry MJ, Fowler FJ, Chang YC, Liss CL, Wilson H, and Stek M Jr: The American Urological Association symptom index: does mode of administration affect its psychometric properties? J Urol 154: 1056-1059, 1995.
43. Plante M, Corcos J, Gregoire I, Belanger MF, Brock G, and Rossingol M: The international prostate symptom score: physician versus self-administration in the quantification of symptomatology. Urology 47: 326-328, 1996.
44. Castro JE, Griffiths HJL, and Shackman R: Significance of signs and symptoms in benign prostatic hypertrophy. Br Med J 2: 598-601, 1969.
45. Birkhoff JD, Wiederhorn AR, Hamilton ML, and Zinsser HH: Natural history of benign prostatic hypertrophy and acute urinary retention. Urology 7: 48-52, 1976.
46. Boyarsky S, Jones G, Paulson DF, and Prout GR Jr: A new look at bladder neck obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourinary Surg 68: 29-32, 1977.
47. Abrams PH, and Feneley RCL: The significance of the symptoms associated with bladder outflow obstruction. Urol Int 33: 171-174, 1978.
48. Madsen PO, and Iversen P: A point system for selecting operative candidates, in Hinman F Jr (Ed): Benign Prostatic Hypertrophy. New York, Springer-Verlag, 1983, pp 763-765.
49. Peters CA, and Walsh PC: The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 317: 599-604, 1987.
50. Fowler FJ, Wennberg JE, Timothy RP, Barry MJ, Mulley AG, and Hanley D: Symptom status and quality of life following prostatectomy. JAMA 259: 3018-3022, 1988.
51. Lidgi S, Moskovitz B, Groshar D, Embon OM, Levin DR, and Sazbon A: Preoperative prediction of results of prostatectomy by a symptom score and radionuclide uroflowmetry. Eur Urol 16: 97-100, 1989.
52. Sommer P, Nielsen KK, Bauer T, Kristensen ES, Herman GG, and Nordling J: Voiding patterns in men evaluated by a questionnaire survey. Br J Urol 65: 155-160, 1990.
53. Epstein RS, Deverka PA, Chute CG, Lieber MM, Oesterling JE, Panser L, Schwartz SW, Guess HA, and Patrick D: Urinary symptom and quality of life questions indicative of obstructive benign prostatic hyperplasia. Urology 38(suppl 1): 20-26, 1991.
54. Epstein RS, Deverka PA, Chute CG, Panser L, Oesterling JE, Lieber MM, Schwartz SW, and Patrick D: Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 45: 1431-1445, 1992.
55. Blaivas JG: Urinary symptoms and symptom scores. J Urol 150: 1714, 1993.
56. Riehmann M, and Jønler M: Controversies about the clinical assessment of benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 172: 81-94, 1995.
57. Fowler FJ: Patient reports of symptoms and quality of life following prostate surgery. Eur Urol 20(suppl 1): 44-49, 1991.
58. O'Leary MP, Barry MJ, and Fowler FJ Jr: Hard measures of subjective outcomes: validating symptom indexes in urology. J Urol 148: 1546-1548, 1564, 1992.
59. Cockett AT, Aso Y, Denis L, Khoury S, Barry M, Carlton CE, Coffey D, Fitzpatrick J, Griffiths K, Hald T, et al: World Health Organization Consensus Committee recommendations concerning the diagnosis of BPH. Prog Urol 1: 957-972, 1991.
60. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, and Mebust WK: Measuring disease-specific health status in men with benign prostatic hyperplasia: measurement committee of the American Urological Association. Med Care 33(suppl 4): AS145-AS155, 1995.
61. Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E, and Lepor H: Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 154: 1770-1774, 1995.
62. Barry MJ: Medical outcomes research and benign prostatic hyperplasia. Prostate 3(suppl): 61-74, 1990.
63. Fowler FJ Jr, and Barry MJ: Quality of life assessment for evaluating benign prostatic hyperplasia treatments: an example of using a condition-specific index. Eur Urol 24(suppl 1): 24-27, 1993.
64. Eri LM, and Tveter KJ: Measuring the quality of life of patients with benign prostatic hyperplasia: assessment of the usefulness of a new quality of life questionnaire specially adapted to benign prostatic hyperplasia patients. Eur Urol 21: 257-262, 1992.
65. Lukacs B, McCarthy C, Grange JC, and the QOL BPH study group in general practice: Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. Eur Urol 24(suppl 1): 34-40, 1993.
66. Rutkow IM: Urological operations in the United States: 1979 to 1984. J Urol 135: 1206-1208, 1986.
67. Lepor H, and Rigaud G: The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J Urol 143: 533-537, 1990.
68. Bruskewitz RC, and Riehmann M: New therapies for benign prostatic hyperplasia. Mayo Clin Proc 67: 493-495, 1992.
69. Graversen PH, Gasser TC, Wasson JH, Hinman F Jr, and Bruskewitz RC: Controversies about indications for transurethral resection of the prostate. J Urol 141: 475-481, 1989.
70. Roehrborn CG: Objective and subjective response criteria to diagnose benign prostatic hyperplasia. Eur Urol 24(suppl 1): 2-11, 1993.
71. Poulsen AL, Schou J, Puggaard L, Torp-Pedersen S, and Nordling J: Prostatic enlargement, symptomatology and pressure/flow evaluation: interrelations in patients with symptomatic BPH. Scand J Urol Nephrol Suppl 157: 67-73, 1994.
72. Lepor H, Sunaryadi I, Hartanto V, and Shapiro E: Quantitative morphometry of the adult human bladder. J Urol 148: 414-417, 1992.
73. Elbadawi A: Functional pathology of urinary bladder muscularis: the new frontier in diagnostic uropathology. Semin Diagn Pathol 10: 314-354, 1993.
74. Holm NR, Horn T, and Hald T: Detrusor in ageing and obstruction. Scand J Urol Nephrol 29: 45-49, 1995.
75. Isaacs JT, and Coffey DS: Etiology and disease process of benign prostatic hyperplasia. Prostate 2(suppl): 33-50, 1989.
76. Isaacs JT: Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl 3: 1-7, 1990.
77. Jørgensen JB: Clinical evaluation of voiding symptoms and uroflowmetry in elderly men. Dan Med Bull 42: 244-256, 1995.
78. Lepor H, and Machi G: Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 42: 36-41, 1993.
79. Chancellor MB, and Rivas DA: American Urological Association symptom index for women with voiding symptoms: lack of index specificity for benign prostate hyperplasia. J Urol 150: 1706-1709, 1993.
80. Tarlov AR, Ware JE Jr, Greenfield S, Nelson EC, Perrin E, and Zubkoff M: The Medical Outcomes Study: an application of methods for monitoring the results of medical care. JAMA 262: 925-930, 1989.
81. Jolleys JV, Donovan JL, Nanchahal K, Peters TJ, and Abrams P: Urinary symptoms in the community: how bothersome are they? Br J Urol 74: 551-555, 1995.
82. Brody EM, and Kleban MH: Physical and mental health symptoms of older people: who do they tell? J Am Geriatr Soc 29: 442-449, 1981.
83. Gjørup T, Hendriksen C, Lund E, and Stromgard E: Is growing old a disease? A study of the attitudes of elderly people to physical symptoms. J Chronic Dis 40: 1095-1098, 1987.
84. Williamson J, Stokoe IH, Gray S, Fisher M, Smith A, McGhee A, and Stephenson E: Old people at home: their unreported needs. Lancet 1: 1117-1120, 1964.
85. Williams EI, Bennett FM, Nixon JV, Nicholson MR, and Gabert J: Sociomedical study of patients over 75 in general practice. Br Med J 2: 445-448, 1972.
86. Matzkin H, Greenstein A, Prager-Geller T, Sofer M, and Braf Z: Do reported micturition symptoms on the American Urological Association Questionnaire correlate with 24-hour home uroflowmetry recordings? J Urol 155: 197-199, 1996.
87. Riehmann M, and Bruskewitz R: Transurethral incision of the prostate and bladder neck. J Androl 12: 415-422, 1991.
88. Gerber GS: Lasers in the treatment of benign prostatic hyperplasia. Urology 45: 193-199, 1995.
89. Riehmann M, and Bruskewitz RC: Treatment of benign prostatic hyperplasia, in Bahnson R (Ed): Management of Urologic Disorders. London, Mosby-Year Book Europe, 1994, pp 1-14.
90. Ouslander JG: Causes, assessment, and treatment of incontinence in the elderly. Urology 36: 25-35, 1990.
91. Riesenberg D, and Glass RM: The medical outcomes study. JAMA 262: 943, 1989.